{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:12:46Z","timestamp":1793373166458,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Recent studies have shown that haploidentical hematopoietic stem cell transplantation supported by third-party cord blood (haplo-cord-HSCT) results in rapid hematopoietic recovery, low incidences of graft-versus-host disease (GVHD), and relapse of hematologic malignancies. However, few reports on haploidentical peripheral blood stem cell transplantation supported by third-party cord blood (haplo-cord-PBSCT) have been published. To evaluate the outcomes of patients who underwent haplo-cord-PBSCT or human leukocyte antigen (HLA)-matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT), we retrospectively reviewed the clinical data of patients with hematologic malignancies who underwent haplo-cord-PBSCT (n = 93) or MSD-PBSCT (n = 72) in our hospital from March 2017 to December 2020. In the haplo-cord-PBSCT and MSD-PBSCT groups, the median time for neutrophil and platelet engraftment was 13 vs. 12 days (<jats:italic>p<\/jats:italic> = 0.07) and 16 vs. 13 days (<jats:italic>p<\/jats:italic> = 0.06), respectively. The 30-day cumulative incidences of neutrophil engraftment were 100.0% and 98.6% (<jats:italic>p<\/jats:italic> = 0.12). The 100-day cumulative incidences of platelet engraftment were 96.8% and 98.6% (<jats:italic>p<\/jats:italic> = 0.01). The 100-day cumulative incidences of grade II\u2013IV and grade III\u2013IV acute GVHD were 29.1% vs. 23.6% (<jats:italic>p<\/jats:italic> = 0.42) and 9.7% vs. 4.2% (<jats:italic>p<\/jats:italic> = 0.18). The cumulative incidences of total and moderate\/severe chronic GVHD at 1 year were 26.5% vs. 17.4% and 8.1% vs. 4.5%, respectively, and at 3 years were 34.7% vs. 34.3% (<jats:italic>p<\/jats:italic> = 0.60) and 13.6% vs. 10.6% (<jats:italic>p<\/jats:italic> = 0.49), respectively. The cumulative incidences of relapse at 1 year were 9.3% and 7.2% and at 3 years were 17.0% and 17.0% (<jats:italic>p<\/jats:italic> = 0.98). Non-relapse mortality (NRM) at 1 year was 14.6% and 8.6% and at 3 years was 17.4% and 8.6% (<jats:italic>p<\/jats:italic> = 0.13) in two groups. The probabilities of overall survival (OS), disease-free survival (DFS), and GVHD-free\/relapse-free survival (GRFS) at 1 year were 81.7% vs. 88.6%, 76.1% vs. 84.2%, and 71.7% vs. 79.7%, respectively, and at 3 years were 78.7% vs. 79.0%, 65.6% vs. 74.4%, and 55.5% vs. 63.6%, respectively, in the corresponding group, <jats:italic>p<\/jats:italic> &amp;gt; 0.05. In conclusion, for patients with acute myeloid leukemia\/myelodysplastic syndrome (AML\/MDS) and acute lymphoid leukemia (ALL), haplo-cord-PBSCT results in similar outcomes compared with MSD-PBSCT, and it may be a valid alternative transplantation method.<\/jats:p>","DOI":"10.3389\/fonc.2022.922120","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:54:31Z","timestamp":1657803271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Tingting","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.34","article-title":"Use of Haploidentical Stem Cell Transplantation Continues to Increase: The 2015 European Society for Blood and Marrow Transplant Activity Survey Report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.18","article-title":"Hematopoietic Stem Cell Transplantation Activity Worldwide in 2012 and a Swot Analysis of the Worldwide Network for Blood and Marrow Transplantation Group Including the Global Survey","volume":"51","author":"Niederwieser","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01431-6","article-title":"Hematopoietic Stem Cell Transplantation Activity in China 2019: A Report From the Chinese Blood and Marrow Transplantation Registry Group","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-Dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin as an Effective Strategy for Gvhd Prevention in Haploidentical Patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247296","article-title":"Post-Transplant Cyclophosphamide Versus Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prevention in Haploidentical Transplantation for Adult Acute Lymphoblastic Leukemia","volume":"106","author":"Nagler","year":"2021","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","article-title":"Haploidentical Allograft Is Superior to Matched Sibling Donor Allograft in Eradicating Pre-Transplantation Minimal Residual Disease of Aml Patients as Determined by Multiparameter Flow Cytometry: A Retrospective and Prospective Analysis","volume":"10","author":"Chang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0686-3","article-title":"Haploidentical Transplantation Might Have Superior Graft-Versus-Leukemia Effect Than Hla-Matched Sibling Transplantation for High-Risk Acute Myeloid Leukemia in First Complete Remission: A Prospective Multicentre Cohort Study","volume":"34","author":"Yu","year":"2020","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.023","article-title":"Superior Graft-Versus-Leukemia Effect Associated With Transplantation of Haploidentical Compared With Hla-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison","volume":"17","author":"Wang","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00859-5","article-title":"Haploidentical Versus Hla-Matched Sibling Transplantation for Refractory Acute Leukemia Undergoing Sequential Intensified Conditioning Followed by Dli: An Analysis From Two Prospective Data","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.189258","article-title":"Outcomes of Hematopoietic Stem Cell Transplantation From Unmanipulated Haploidentical Versus Matched Sibling Donor in Patients With Acute Myeloid Leukemia in First Complete Remission With Intermediate or High-Risk Cytogenetics: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"103","author":"Salvatore","year":"2018","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.232","article-title":"Is There a Stronger Graft-Versus-Leukemia Effect Using Hla-Haploidentical Donors Compared With Hla-Identical Siblings","volume":"30","author":"Ringd\u00e9n","year":"2016","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41409-019-0546-9","article-title":"Cord Blood Research, Banking, and Transplantation: Achievements, Challenges, and Perspectives","volume":"55","author":"Mayani","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01474-0","article-title":"Comparing Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia","volume":"36","author":"Shimomura","year":"2021","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-021-00461-w","article-title":"Comparison of Clinical Outcomes Between Unrelated Single Umbilical Cord Blood and \u201cEx-Vivo\u201d T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies","volume":"17","author":"G\u00f3mez-Santos","year":"2021","journal-title":"World J Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007535","article-title":"Double Unrelated Umbilical Cord Blood Vs Hla-Haploidentical Bone Marrow Transplantation: The Bmt Ctn 1101 Trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000200","article-title":"Haploidentical Vs Haplo-Cord Transplant in Adults Under 60 Years Receiving Fludarabine and Melphalan Conditioning","volume":"3","author":"van Besien","year":"2019","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.154","article-title":"Combination of a Haploidentical Sct With an Unrelated Cord Blood Unit: A Single-Arm Prospective Study","volume":"49","author":"Chen","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733326","article-title":"Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using Atg\/Ptcy Increases Survival of Relapsed\/Refractory Hematologic Malignancies","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0666-2","article-title":"Haploidentical Stem Cells Combined With a Small Dose of Umbilical Cord Blood Transplantation Exert Similar Survival Outcome of Hla-Matched Stem Cells Transplantation in T-Cell Acute Lymphoblastic Leukemia","volume":"55","author":"Xu","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.229","article-title":"Myeloablative Conditioning Regimens With Combined of Haploidentical and Cord Blood Transplantation for Myelodysplastic Syndrome Patients","volume":"53","author":"Ke","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1695053","article-title":"Comparison of Outcomes of Haploidentical Donor Hematopoietic Stem Cell Transplantation Supported by Third-Party Cord Blood With Hla-Matched Unrelated Donor Transplantation","volume":"61","author":"Lyu","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute Lymphoblastic Leukemia, Version 2.2021, Nccn Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"Nccn Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V89.6.2079","article-title":"International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0204-7","article-title":"Ebmt-Nih-Cibmtr Task Force Position Statement on Standardized Terminology & Guidance for Graft-Versus-Host Disease Assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring Therapeutic Response in Chronic Graft-Versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: Iv. The 2014 Response Criteria Working Group Report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31228","article-title":"Bone Marrow Versus Mobilized Peripheral Blood Stem Cells in Haploidentical Transplants Using Posttransplantation Cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631625","article-title":"G-Csf-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221076050","article-title":"A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus Hla-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients","volume":"31","author":"Lu","year":"2022","journal-title":"Cell Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.72.8428","article-title":"Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow as a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-0014-8","article-title":"Improved Clinical Outcomes of Rhg-Csf-Mobilized Blood and Marrow Haploidentical Transplantation Compared to Propensity Score-Matched Rhg-Csf-Primed Peripheral Blood Stem Cell Haploidentical Transplantation: A Multicenter Study","volume":"59","author":"Zhao","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01047-2","article-title":"Low Dose Anti-Thymocyte Globulin With Low Dose Posttransplant Cyclophosphamide (Low Dose Atg\/Ptcy) Can Reduce the Risk of Graft-Versus-Host Disease as Compared With Standard-Dose Anti-Thymocyte Globulin in Haploidentical Peripheral Hematopoietic Stem Cell Transplantation Combined With Unrelated Cord Blood","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000262","article-title":"Suppressive Characteristics of Umbilical Cord Blood-Derived Regulatory T Cells After Ex Vivo Expansion on Autologous and Allogeneic T Effectors and Various Lymphoblastic Cells","volume":"42","author":"Vanichapol","year":"2019","journal-title":"J Immunother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical Cord Blood-Derived T Regulatory Cells to Prevent Gvhd: Kinetics, Toxicity Profile, and Clinical Effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0821-9","article-title":"Comparison of the Outcomes After Haploidentical and Cord Blood Salvage Transplantations for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation","volume":"55","author":"Harada","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.transci.2012.08.004","article-title":"Cellular Mechanism for Granulocyte-Colony Stimulating Factor in the Prevention of Graft-Versus-Host Disease in Combined Bone Marrow and Peripheral Blood Transplantation for Hematological Malignancies: The Composition in Collection","volume":"48","author":"Zhang","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2009.05.005","article-title":"Expression Profiles of Adhesion Molecules on Na\u00efve T Cells in Bone Marrow Grafts of Healthy Donors Treated With Granulocyte Colony-Stimulating Factor","volume":"21","author":"Chang","year":"2009","journal-title":"Transpl Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two Dose Levels of Rabbit Antithymocyte Globulin as Graft-Versus-Host Disease Prophylaxis in Haploidentical Stem Cell Transplantation: A Multicenter Randomized Study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.271445","article-title":"Comparison of Immune Reconstitution Between Anti-T-Lymphocyte Globulin and Posttransplant Cyclophosphamide as Acute Graft-Versus-Host Disease Prophylaxis in Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation","volume":"107","author":"Massoud","year":"2022","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.002","article-title":"Cord Haploidentical Non-In Vitro T Cell Depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse of Refractory Acute Leukemia","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.021","article-title":"Low Cd34 Dose Is Associated With Poor Survival After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"20","author":"T\u00f6rl\u00e9n","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.922120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:54:38Z","timestamp":1657803278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.922120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":43,"alternative-id":["10.3389\/fonc.2022.922120"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.922120","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"922120"}}